Market research
HGF2.F Catalyst Biosciences, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 19M
- P/E ratio
- Not available
- Analyst target
- 16.6
- Dividend yield
- Not available
- Beta
- 1.29
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US14888D2080
- Market cap
- 19M
- P/E ratio
- Not available
- Analyst target
- 16.6
- Dividend yield
- Not available
- Beta
- 1.29
About
About Catalyst Biosciences, Inc
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HGF2.F discussion.
5 years, 5 months ago
Catalyst Biosciences, Inc is currently in a long term downtrend where the price is trading 21.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.6.
Catalyst Biosciences, Inc's total revenue rose by inf% to $2M since the same quarter in the previous year.
Its net income has dropped by 38.9% to $-19M since the same quarter in the previous year.
Finally, its free cash flow fell by 173.9% to $-22M since the same quarter in the previous year.
Based on the above factors, Catalyst Biosciences, Inc gets an overall score of 2/5.